258 related articles for article (PubMed ID: 33883587)
1. The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study.
Hong JR; Jeong H; Kim H; Yang HS; Hong JY; Kim SM; Cho YA; Lee YW; Choe YB; Ahn KJ
Sci Rep; 2021 Apr; 11(1):8588. PubMed ID: 33883587
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
Ahlehoff O; Skov L; Gislason G; Lindhardsen J; Kristensen SL; Iversen L; Lasthein S; Gniadecki R; Dam TN; Torp-Pedersen C; Hansen PR
J Intern Med; 2013 Feb; 273(2):197-204. PubMed ID: 22963528
[TBL] [Abstract][Full Text] [Related]
5. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Takeshita J; Wang S; Shin DB; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Robertson AD; Linn KA; Shinohara RT; Troxel AB; Van Voorhees AS; Gelfand JM
J Am Acad Dermatol; 2014 Dec; 71(6):1167-75. PubMed ID: 25260564
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
Carpentieri A; Pacello L; De Marco IM; Loiacono A; Picconi O; Loconsole F
J Dermatolog Treat; 2016 Oct; 27(5):399-405. PubMed ID: 26822691
[TBL] [Abstract][Full Text] [Related]
8. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
[TBL] [Abstract][Full Text] [Related]
9. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
[TBL] [Abstract][Full Text] [Related]
11. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Kojanova M; Fialova J; Cetkovska P; Gkalpakiotis S; Jircikova J; Dolezal T; Arenberger P;
Int J Dermatol; 2017 Apr; 56(4):428-434. PubMed ID: 28181669
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
Shalom G; Zisman D; Bitterman H; Harman-Boehm I; Greenberg-Dotan S; Dreiher J; Feldhamer I; Moser H; Hammerman A; Cohen Y; Cohen AD
JAMA Dermatol; 2015 May; 151(5):533-8. PubMed ID: 25797026
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis.
Wu JJ; Joshi AA; Reddy SP; Batech M; Egeberg A; Ahlehoff O; Mehta NN
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1320-1326. PubMed ID: 29573294
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancy in patients with psoriasis according to treatment modalities in Korea: a nationwide cohort study.
Hong JY; Ahn J; Won S; Kim SM; Cho YA; Kim CY; Sung JY; Yu DA; Lee YW; Choe YB
Sci Rep; 2022 Nov; 12(1):20690. PubMed ID: 36450739
[TBL] [Abstract][Full Text] [Related]
16. Psoriatic arthritis risk in psoriasis patients prescribed acitretin versus disease-modifying antirheumatic drugs: a nationwide cohort study.
Lin TL; Chang YL; Ho HJ; Chen YJ; Wu CY
Rheumatology (Oxford); 2024 May; 63(6):1624-1631. PubMed ID: 37656926
[TBL] [Abstract][Full Text] [Related]
17. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
19. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.
Abuabara K; Lee H; Kimball AB
Br J Dermatol; 2011 Nov; 165(5):1066-73. PubMed ID: 21777216
[TBL] [Abstract][Full Text] [Related]
20. Serious infections and tuberculosis in psoriasis patients receiving systemic therapy in Korea: a nationwide population-based cohort study.
Cho YA; Ahn J; Hong JY; Won S; Kim SM; Sung JY; Kim CY; Yu DA; Lee YW; Choe YB
Eur J Dermatol; 2023 Jun; 33(3):287-295. PubMed ID: 37594337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
